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Complete bone marrow inﬁltration with profound pancytopenia is very uncommon in breast
cancer. Bone marrow metastasis can frequently occur following development of metastatic
breast cancer. However, bone marrow failure as the herald of this disease is not typically seen.
Very limited data exists as to the safest and most efﬁcacious manner to treat patients with
profound pancytopenia due to metastatic solid tumor involvement. In this case, the patient's
thrombocytopenia was particularly worrisome, requiring daily platelet transfusions. There
was also concern that cytotoxic chemotherapy would exacerbate the patient's thrombocyto-
penia and increase bleeding risk. The patient's dramatic response to chemotherapy with full
platelet recovery is also highly unusual. For our patient, continuous doxorubicin successfully
“unpacked” the bone marrow despite a low baseline platelet level, and without increasing the
need for more frequent platelet transfusion or risk of catastrophic bleeding. Given the rarity of
this presentation, it is currently unknown if the majority of similar patients experience near full
recovery of hematopoietic function after initiation of appropriate systemic treatment for
metastatic disease.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
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Breast cancer is the most common malignancy in women
and number one cause of death in women between the agesen access article under the CC BY-NC-ND license
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disease, considered incurable, is rarely seen at the time of
initial diagnosis, approximately 20% of women with oper-
able breast cancer eventually relapse, with about 70% of the
relapses as distant metastases [2–5]. Approximately 80% of
women with metastatic breast cancer have skeletal metas-
tases, which are often the result of bone marrow inﬁltra-
tion of malignant cells with subsequent progression and
invasion of the skeletal cortex [6–9]. The most common
complications of skeletal metastases are pathologic frac-
tures, spinal cord compression as the result of vertebral
compression fracture or extension of the tumor beyond the
epidural space, and hypercalcemia [7–9]. Furthermore,
skeletal metastases sometimes require surgery or radiation
therapy to treat pain or an impending fracture. Bone
marrow metastases result in the invasion and destruction
of the bone tissue matrix by tumor cells [6]. Although bone
marrow inﬁltration by metastases is commonly present
among breast cancer patients, total bone marrow inﬁltra-
tion resulting in profound pancytopenia is extremely rare
[6,10].2. Case report
A 62 year-old female presented with increased fatigue that
was interfering with her activities of daily living. Her
previous medical history was remarkable only for hyperten-
sion. Her family history included lung cancer in her mother.
On physical exam, she was ill-appearing and fatigued. Sclera
were anicteric. Lips were dry and oral mucosa was notable
for blood tinged secretions. Lungs were clear to ausculta-
tion bilaterally. Cardiovascular exam was normal, with no
murmurs, rubs or gallops appreciated. Abdomen was soft
and nontender without organomegaly. Her breast exam wasFigure 1 The bone marrow biopsy shows that the hematopoiet
carcinoma inﬁltrating individually and in small clusters, and compris
rim of cytoplasm and occasional intracytoplasmic vacuoles.notable for a ﬁxed, 1 cm left axillary lymph node. Neither
breast had a palpable mass or skin changes. Peripheral
blood laboratory tests indicated severe pancytopenia. Her
white blood cell (WBC) count was 3.2 K/μL, hemoglobin
(Hgb) was 6.8 g/dL, and platelet count was 3 K/μL. Multiple
imaging studies, including computed tomography (CT) of the
chest, abdomen and pelvis, as well as a bone scintography
were completed as part of the initial diagnostic work up.
Chest CT revealed left axillary adenopathy and a medial,
nodular left breast lesion. The bone scintography scan
showed diffuse skeletal metastatic disease involving multi-
ple vertebrae and the pelvis. A mammogram had also been
performed and showed an irregular spiculated nodule in the
upper inner left breast. The patient subsequently under-
went a core needle biopsy of an enlarged left axillary lymph
node. The biopsy revealed a metastatic lobular carcinoma
strongly positive for both estrogen and progesterone recep-
tors (ER and PR) and negative for HER2 and E-cadherin by
immunohistochemical staining.
To further evaluate the patient's profound pancytopenia,
which required frequent transfusion of packed red blood
cells (pRBC) and platelets, the patient underwent a bone
marrow biopsy. The pathology showed that the metastatic
carcinoma had entirely replaced the bone marrow
(Figure 1). The tumor cells were positive by immunohisto-
chemical staining for cytokeratin AE1/AE3, ER and PR, but were
negative for HER2, consistent with metastatic breast cancer.
After much discussion of the risks and beneﬁts of therapy in
view of profound pancytopenia, the patient initiated systemic
therapy with doxorubicin administered as a continuous three
day infusion (20 mg/m2/day) on a 21 day cycle in the inpatient
setting. A continuous infusion of doxorubicin was selected
based on small, prior studies suggesting that acute and chronic
toxicities, including bone marrow suppression, may be lessened
when doxorubicin is administered as a continuous versus bolusic elements are entirely replaced by ﬁbrosis and metastatic
ed of intermediate sized cells with round to ovoid nuclei, a thin
G. Pahouja et al.30infusion [11–13]. The patient ultimately received 3 cycles of
this therapy. During the ﬁrst cycle, the doxorubicin dose was
reduced by 50% due to increased transaminases that normal-
ized with subsequent cycles of therapy. The second cycle
was given at full dose, but was complicated by febrile
neutropenia requiring hospitalization. The doxorubicin dose
was therefore reduced by 25% during the third cycle. After
3 cycles of therapy, continuous doxorubicin was switched to
monthly liposomal doxorubicin (40 mg/m2) for ease of
administration in the outpatient setting since the patient's
platelets had sufﬁciently recovered. As shown in Figure 2,
the patient's pancytopenia steadily improved after initiation
of chemotherapy. Approximately four months after com-
mencing treatment, her WBC rose to 5.4 K/μL, Hgb
increased to 11.6 g/dL and platelet count improved to
131 K/μL. Approximately thirteen months after beginning
the treatment, the patient experienced a near full recovery
from her pancytopenia with no evidence of anemia or
thrombocytopenia. Her laboratory tests showed WBC of
4.8 K/μ, RBC of 4.00 M/μL, Hgb of 12.8 g/dL and platelet
count of 160 K/μL at that time, indicating a remarkable
response to treatment (Figure 2). After four cycles of
liposomal doxorubicin, the patient was transitioned to
endocrine therapy with an aromatase inhibitor, letrozole.0
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Figure 2 Patient's platelet (A), white blood cell (B) and
hemoglobin (C) levels throughout treatment highlighting hema-
topoietic recovery after continuous doxorubicin therapy.Her laboratory proﬁle remained stable 43 months after
initiation of continuous doxorubicin. In her last 12 months
of life, her disease progressed in the liver, bone, orbit and
brain. She was treated with radiation to the orbital
metastasis and brain metastases, but declined further
systemic chemotherapy. In her last month of life, her
platelets dropped to 15 with normal white blood count
and hemoglobin levels. She ultimately died from complica-
tions of metastatic breast cancer 44 months after her initial
diagnosis.3. Discussion
Complete bone marrow inﬁltration with profound pancyto-
penia is very uncommon in breast cancer. Bone marrow
metastasis can frequently occur following development of
metastatic breast cancer [14]. However, bone marrow fail-
ure as the herald of this disease is not typically seen. Very
limited data exists as to the safest and most efﬁcacious
manner to treat patients with profound pancytopenia due to
metastatic solid tumor involvement.
In this case, the patient's thrombocytopenia was particu-
larly worrisome, requiring daily platelet transfusions. There
was also concern that cytotoxic chemotherapy would exacer-
bate the patient's thrombocytopenia and increase bleeding
risk. The patient's dramatic response to chemotherapy with
full platelet recovery is also highly unusual. For our patient,
continuous doxorubicin successfully “unpacked” the bone
marrow despite a low baseline platelet level, and without
increasing the need for more frequent platelet transfusion or
risk of catastrophic bleeding. Given the rarity of this pre-
sentation, it is currently unknown if the majority of similar
patients experience near full recovery of hematopoietic
function after initiation of appropriate systemic treatment
for metastatic disease.
Pancytopenia is not a common presentation in patients
with metastatic breast cancer. In several studies, pancyto-
penia was noted as the consequence of adjuvant che-
motherapy with alkylating agents and topoisomerase II
inhibitors rather than metastatic disease [15]. Some have
suggested that the use of growth factor support such as
ﬁlgrastim or peg-ﬁlgrastim may also contribute to the risk of
developing pancytopenia related to myelodysplastic syn-
drome or acute myeloid leukemia, although that association
has not been completely established [16]. Saito et al.
reported on a metastatic breast cancer patient with pancy-
topenia who had evidence of concurrent therapy-related
acute myeloid leukemia and bone marrow metastasis [17].
In our case, bone marrow inﬁltration with metastatic
breast cancer was the primary cause of pancytopenia. This
has rarely been described in the literature and includes both
patients with both positive and negative outcomes from
therapy. Several reports highlight patients who have
responded to systemic therapy including low dose capeci-
tabine, endocrine therapy and trastuzumab monotherapy
[28–32]. As expected not all patients respond to therapy.
Sasada et al. reported on a case of a patient with bone
marrow metastasis from breast cancer [18]. The patient
developed pancytopenia with disseminated intravascular
coagulation (DIC) and was given weekly paclitaxel therapy
with blood transfusion and G-CSF injections. Therapy was
31Stabilization of bone marrow inﬁltration by metastatic breast cancer with continuous doxorubicinineffective and the patient died of gastrointestinal hemor-
rhage due to complications of pancytopenia that were likely
caused by DIC and metastatic disease [18]. Our patient
experienced similar bone marrow metastasis and pancyto-
penia, but was able to achieve sustained disease control
through doxorubicin chemotherapy followed by aromatase
inhibitor therapy, without bleeding complications. In addi-
tion, laboratory tests at the time of diagnosis did not show
any evidence of DIC in our case.
In addition to continuous doxorubicin, our patient received
zoledronic acid as a part of management of osseous metas-
tasis from breast cancer. Many studies have focused on the
prevention of breast cancer due to subclinical bone marrow
metastasis caused by dormant disseminated tumor cells
(DTCs) in the bone marrow [19–21]. Although DTCs appear
to be associated with a higher risk of distant recurrence, they
are not known to cause abnormalities in peripheral blood
laboratory tests. Solomayer et al. demonstrated the impact
of zoledronic acid on DTCs in primary breast cancer patients
[22]. The authors found that DTC-positive patients treated
with zoledronic acid were more likely to become DTC-
negative following a 12 month treatment interval and
concluded that treatment with zoledronic acid improved
the elimination of DTCs [22]. The role of bisphosphonates
in preventing skeletal metastases in patients with high risk
early stage breast cancer is controversial [20,23–27]. The
contribution of zoledronic acid in bone marrow recovery in
this instance is not known.
4. Conclusion
Breast cancer has a tendency to metastasize to the bone
marrow, but does not commonly cause bone marrow failure.
The case presented describes a patient who developed
complete bone marrow inﬁltration by estrogen receptor
positive metastatic breast cancer that led to transfusion
dependent pancytopenia. The patient received treatment
with continuous doxorubicin and zoledronic acid followed by
endocrine therapy, which resulted in complete recovery of
normal bone marrow function for 3 years. Drug therapy is a
consideration in patients with bone marrow inﬁltration with
good performance status.
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